Pancreatic Cancer Research

ResearcherPennsylvania State UniversityNo recent work listed

Joyce Y. Wong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3084-9374; OpenAlex author ID A5101931868. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
7
Papers, trials and grants by year

2016: 2 papers · 2017: 5 papers · 2018: 3 papers · 2019: 1 paper

Papers 11

  1. A nomogram for predicting survival of patients with locally advanced pancreatic cancer treated with chemoradiotherapy: an editorial comment. Co-author DOI 10.21037/atm.2019.01.75↗
  2. Minimally invasive surgical approaches offer earlier time to adjuvant chemotherapy but not improved survival in resected pancreatic cancer. Last author DOI 10.1007/s00464-017-5937-7↗
  3. Time to Surgery: a Misguided Quality Metric in Early Stage Pancreatic Cancer. Last author DOI 10.1007/s11605-018-3730-0↗
  4. Correlation of clinical and pathological staging and response to neoadjuvant therapy in resected pancreatic cancer. Last author DOI 10.1016/j.ijsu.2018.01.043↗
  5. Trends in utilization of neoadjuvant therapy and short-term outcomes in resected pancreatic cancer. Last author DOI 10.1016/j.amjsurg.2016.08.015↗
  6. Greater lymph node retrieval and lymph node ratio impacts survival in resected pancreatic cancer. Last author DOI 10.1016/j.jss.2017.06.076↗
  7. "Stealth dissemination" of macrophage-tumor cell fusions cultured from blood of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0184451↗
  8. Utilization and trends in palliative therapy for stage IV pancreatic adenocarcinoma patients: a U.S. population-based study. Last author DOI 10.21037/jgo.2017.06.01↗
  9. Prognostic impact of carbohydrate antigen 19-9 level at diagnosis in resected stage I-III pancreatic adenocarcinoma: a U.S. population study. Last author DOI 10.21037/jgo.2017.07.04↗
  10. Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer. Last author DOI 10.1002/cncr.30163↗
  11. Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base. Last author DOI 10.1016/j.ijsu.2016.08.523↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Katelin Anne Mirkin · 9 shared papers, 2016–2018 · strength 0.99
  2. Christopher S. Hollenbeak · 9 shared papers, 2016–2018 · strength 0.99
  3. Audrey Stokes Kulaylat · 1 shared paper, 2017 · strength 0.10
  4. Niraj Jaysukh Gusani · 1 shared paper, 2017 · strength 0.10
  5. Gary A. Clawson · 1 shared paper, 2017 · strength 0.06
  6. Thomas Abraham · 1 shared paper, 2017 · strength 0.06
  7. Gail L. Matters · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.